Upstream Bio, Inc.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, initially focused on severe respiratory disorders. Its main product candidate, verekitug, is a monoclonal antibody that targets and inhibits the TSLP receptor. Upstream Bio is studying verekitug in Phase 2 trials for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic obstructive pulmonary disease (COPD), and in a long-term safety and efficacy study for severe asthma. The company reported positive top-line results from its CRSwNP and severe asthma Phase 2 trials and initiated its COPD Phase 2 trial in July 2025. Upstream Bio makes no commercial products described here; its business centers on developing verekitug for potential medical use. The company acquired the candidate from Astellas Pharma Inc. in 2021. Upstream Bio is headquartered in Waltham, Massachusetts.
No SEC Form 4 filings for $UPB in the last 30 days.
See all $UPB insider activity →Upstream Bio reported 3Q 2026 revenue of $395K, down 42.2% YoY, and a net loss of $41.19M, up 22.1% YoY. R&D expenses rose due to Phase 3 planning for CRSwNP and increased personnel costs. The company plans Phase 3 trials for severe asthma and CRSwNP in Q1 2027, with data from COPD and severe asthma trials expected in 2H 2027.
Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.
Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class eff
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning UPB (Upstream Bio, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent UPB coverage spans financial news, earnings and corporate actions.
Quarterly results reveal significant revenue decline and larger loss, likely pressuring the stock.
The earnings miss and increased R&D spend likely pressure the stock.
Earnings miss and sizable loss may pressure the stock, though strong cash position supports continued development.
The filing adds concrete clinical and regulatory timeline updates plus cash runway, which can reprice near-term probability-weighted Phase 3 success.
Routine corporate governance update; no new operating/financial guidance or material transaction disclosed.
AlphAI scores every news story that mentions UPB with an AI model for sentiment and relevance, and aggregates insider trades from Upstream Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Upstream Bio reported 3Q 2026 revenue of $395K, down 42.2% YoY, and a net loss of $41.19M, up 22.1% YoY. R&D expenses rose due to Phase 3 planning for CRSwNP and increased personnel costs. The company plans Phase 3 trials for severe asthma and CRSwNP in Q1 2027, with data from COPD and severe asthma trials expected in 2H 2027.
Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.
Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class eff
Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress – Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-o
Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0002022626 false 0002022626 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 09,
Upstream Bio announced it will present new Phase 2 VIBRANT trial data for verekitug, an antagonist to the TSLP receptor, at the ATS 2026 International Conference. The presentations will detail verekitug's clinical effect in chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid asthma and its impact on nasal and blood biomarkers. This data highlights the therapy's potential for severe respiratory disorders.
Upstream Bio (NASDAQ: UPB) has established an at-the-market (ATM) equity program, allowing it to offer and sell up to $150 million worth of its common stock through Leerink Partners LLC. This program provides the company with flexible access to capital, enabling sales of shares over time based on market conditions. Leerink Partners will receive a commission of up to 3.0% of the gross proceeds from these sales, and neither party is obligated to sell a minimum amount of shares.
Upstream Bio's CEO, Rand Sutherland, MD, is scheduled to participate in fireside chats at two major healthcare conferences: the TDCowen Health Care Conference on March 4 and the LeerinkPartners Global Healthcare Conference on March 9. His appearances underscore the company's commitment to engaging in critical industry discussions.
WALTHAM, Mass., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc. ( NASDAQ:UPB ) , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream ...
WALTHAM, Mass., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc. ( Nasdaq: UPB ) , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream ...
